Safety and Immunogenicity of a Self-Amplifying RNA Vaccine Against Crimean-Congo Hemorrhagic Fever

Launched by HDT BIO · Jan 23, 2025

Keywords

ClinConnect Summary

This clinical trial is testing a new vaccine called HDT-321 to see if it is safe and effective against a serious illness called Crimean-Congo hemorrhagic fever (CCHF). The researchers want to find out if different doses of the vaccine can protect people from the virus that causes this disease. They will monitor participants for any side effects and check their blood to see if the vaccine helps their bodies build protection against the virus.

To participate, you need to be a healthy adult between 18 and 64 years old, and you should not have certain health conditions that could make it risky for you to receive the vaccine. Participants will receive one or two doses of the vaccine and will need to keep track of their health for about a week after each dose. The study team will follow up with phone calls and visits to ensure everything is going well. This trial is currently not recruiting participants, so keep an eye out for updates if you're interested!

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Males and non-pregnant females 18 to 64 years of age at the time of signing the ICF.
• • 2. Body mass index (BMI) 17 to 35 inclusive at screening.
• • 3. Considered by the PI or designee to be in good general health as determined by medical history, physical examination, vital sign measurements\*, and clinical laboratory assessments conducted no more than 30 days prior to the first study injection administration.
• • 4. Screening laboratory values within the laboratory reference ranges or considered non-clinically significant (NCS) if within Grade 1 severity on the toxicity grading scale.
• • 5. Negative human immunodeficiency virus (HIV) 1/2 antibody, hepatitis B surface antigen (HBsAg), and hepatitis C virus (HCV) antibody.
• • 6. Women of childbearing potential must agree to use or have practiced true abstinence or use at least one acceptable primary form of contraception3 for at least 30 days prior to the first injection and for 60 days after the last injection. Female participants of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test on the day of and prior to each study injection.
• • 7. Able to understand and comply with planned study procedures and willing to be available for all study required procedures, visits, and telephone calls for the duration of the study.
• • 8. Provide written informed consent before initiation of any study procedures.
• • 9. Willing to abstain from donating whole blood or blood derivatives 30 days prior to screening and for the duration of the study.
• • 10. Willing to refrain from receiving any licensed vaccine within 28 days prior to and after scheduled study injections.
• Exclusion Criteria:
• • 1. Any medical disease or condition that, in the opinion of the participating site PI or appropriate sub-investigator, precludes study participation. Including Acute, subacute, intermittent, or chronic medical diseases or conditions that would place the subject at an unacceptable risk of injury, render the subject unable to meet the requirements of the protocol, or may interfere with the evaluation of responses or the subject's successful completion of the trial. Significant respiratory disease (COPD) requiring daily medications, asthma that is not well controlled, significant cardiovascular disease, history of myocarditis or pericarditis, myocardial infarction, coronary artery bypass surgery or stent placement, or uncontrolled cardiac arrhythmia, Neurological or neurodevelopmental conditions, ongoing malignancy or recent diagnosis of malignancy in the last five years excluding basal cell and squamous cell carcinoma of the skin, blood dyscrasias or significant disorder of coagulation, chronic liver disease, including fatty liver, autoimmune disease, including localized or history of psoriasis or hypothyroidism without a defined non-autoimmune cause and Immunodeficiency of any cause.
• • 2. Abnormal screening electrocardiogram (ECG)
• • 3. History of hypersensitivity or severe reactions to previous vaccinations
• • 4. History of hypersensitivity or severe reactions to products known to contain polyethylene glycol (PEG).
• • 5. Allergy to antibiotics structurally similar to kanamycin (including but not limited to neomycin, streptomycin, tobramycin, and gentamycin).
• • 6. Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immunemodifying drugs within 6 months prior to the first study injection (for corticosteroids: prednisone ≥20 mg/day or equivalent). Intra-articular, inhaled, nasal, and topical steroids are allowed.
• • 7. Received immunoglobulins or any blood products within 60 days prior to enrollment/Day 1.
• • 8. Donated blood products within 30 days prior to enrollment/Day 1.
• • 9. Received an investigational or non-registered medicinal product within 30 days prior to screening.
• • 10. Currently enrolled, or plan to participate, in another clinical trial with an investigational agent to be received during the study period.
• • 11. Received or plans to receive any non-study vaccine within 28 days before and after each study injection.
• • 12. Febrile illness\*, as determined by the participating site PI or appropriate sub-investigator, with or without fever (oral temperature ≥38.0°C/100.4°F), within 24 hours prior to each study injection.
• • 13. Current heavy smoking/vaping (defined as 1 pack or more of cigarettes a day or vaping equivalent\*). \*1-2 mL of 20 mg/mL of nicotine salt
• • 14. Known or suspected alcohol or illicit drug abuse within the past 12 months prior to Study Day 1.
• • 15. Breastfeeding or plans to breastfeed from the time of the first vaccination through 60 days after the last study injection.
• • 16. Participants unlikely to cooperate with the requirements of the study protocol.